-+ 0.00%
-+ 0.00%
-+ 0.00%

Fosun Pharmaceutical announced that the holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. received approval from the State Drug Administration to conduct phase II/III adaptive seamless design clinical trials for the treatment of non-segmental vitiligo; the company plans to conduct related clinical research in China after conditions are met.

Zhitongcaijing·09/08/2026 08:57:04
Listen to the news
Fosun Pharmaceutical announced that the holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. received approval from the State Drug Administration to conduct phase II/III adaptive seamless design clinical trials for the treatment of non-segmental vitiligo; the company plans to conduct related clinical research in China after conditions are met.